Table 2.

Synergy between 3BrPA and geldanamycin in pancreatic cancer cells under normoxia and hypoxia in three independent experiments

CellsConditionEffectIC50 or IC70 of 3BrPA alone (umol/L)IC50 or IC70 of geldanamycin alone (umol/L)IC50 or IC70 of geldanamycin when combined with 50 umol/L PA (umol/L)Combination index
BxPC-3Normoxia50%86.3 ± 6.40.85 ± 0.120.24 ± 0.130.86 ± 0.16
70%190 ± 112.12 ± 0.41.2 ± 0.30.82 ± 0.17
Hypoxia50%90.5 ± 6.70.34 ± 0.110.02 ± 0.020.68 ± 0.07
70%131 ± 8.90.76 ± 0.120.37 ± 0.10.86 ± 0.15
Panc-1Normoxia50%79.2 ± 6.3>100.021 ± 0.04<0.64
70%93.1 ± 5.8>500.76 ± 0.23<0.55
Hypoxia50%76.7 ± 6.84.43 ± 2.20.007 ± 0.0010.65 ± 0.05
70%109 ± 8.5>150.34 ± 0.12<0.48
  • NOTE: The cytotoxicity of a single geldanamycin treatment or combined with 50 umol/L 3BrPA treatment under normoxia or hypoxic environment was measured by MTS assay. Relative cell viability was calculated by normalized intensity to nontreatment cell control under different drug concentrations after 72 h of incubation. IC50s or IC70s were calculated by WinNonlin 5.0 in each experiment.